Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. immune modulation
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books

Refine by
Date

  • This Year
  • Older

Immune Modulation Articles & Analysis

21 news found

Alfa Chemistry Expands Portfolio with High-Purity Marine and Plant-Derived Bioactive Peptides

Alfa Chemistry Expands Portfolio with High-Purity Marine and Plant-Derived Bioactive Peptides

Marine Fish Oligopeptide: These very short chains, sourced from fish, are prized for excellent absorption and potential bioactive properties relevant to cardiovascular health, immune function, and tissue repair. Oyster Peptide: Rich in minerals like zinc and unique amino acids, oyster peptides are explored for their potential role in supporting immune function, ...

ByAlfa Chemistry


Creative Biostructure Expands Its Offerings for Exosomes Isolated from Stem Cell Lines

Creative Biostructure Expands Its Offerings for Exosomes Isolated from Stem Cell Lines

Creative Biostructure's expanded catalog now features exosomes isolated from a variety of stem cell sources, including: l Mesenchymal Stem Cells (MSCs): Known for their ability to differentiate into multiple cell types, MSC-derived exosomes are instrumental in tissue repair and immune modulation. l Human Umbilical Cord Mesenchymal Stem Cells (hUCMSCs): These ...

ByCreative Biostructure


Role of Precision Cut Lung Slices (PCLS) In Advancing COPD Preclinical Research

Role of Precision Cut Lung Slices (PCLS) In Advancing COPD Preclinical Research

Chronic Obstructive Pulmonary Disease (COPD) is a global health burden characterized by persistent airflow limitation and progressive lung damage. Despite extensive research, translating findings from bench to bedside remains a challenge. Precision Cut Lung Slices (PCLS) have emerged as a versatile tool in COPD research, offering unique advantages for understanding disease mechanisms and ...

BySCIREQ - an emka TECHNOLOGIES Company


Creative BioMart Unveils Comprehensive Lectin Portfolio for Diverse Research Applications

Creative BioMart Unveils Comprehensive Lectin Portfolio for Diverse Research Applications

Lectins, a class of carbohydrate-binding proteins, hold immense significance in the scientific realm due to their diverse biological functions, encompassing cell adhesion, signal transduction, and immune modulation. Their versatility has propelled their adoption in various research pursuits, including the exploration of cancer, inflammatory processes, and ...

ByCreative BioMart


Creative Enzymes Unveils a Diverse Range of Premium Extracts for Various Applications

Creative Enzymes Unveils a Diverse Range of Premium Extracts for Various Applications

Mushroom Extracts: Creative Enzymes recognizes the timeless health benefits of mushrooms and offers a range of Mushroom Extracts that encapsulate their remarkable properties. Focusing on immune modulation and antioxidants, these extracts have found their place in dietary supplements and functional foods. ...

ByCreative Enzymes


Creative Enzymes Introduces a Range of Lactobacillus Strains with Enhanced Benefits

Creative Enzymes Introduces a Range of Lactobacillus Strains with Enhanced Benefits

In recent years, extensive research has emphasized the critical role of gut health in maintaining a balanced immune system and overall vitality. Consequently, the demand for effective probiotic solutions has skyrocketed. ...

ByCreative Enzymes


Announcing the Release of MiXCR 4.0, a Powerful Tool for Immunome Profiling

Announcing the Release of MiXCR 4.0, a Powerful Tool for Immunome Profiling

MiXCR 4.0 is enhanced software for analysis of genomics data and building a comprehensive picture of the immune response. Leading pharmaceutical research and development (R&D) teams can leverage MiXCR 4.0 for drug discovery pipelines, and for analyzing DNA sequencing data unraveling genomic information about antibodies, T-cell, and B-cell receptors. ...

ByMi Laboratories


BRIM Biotechnology, Inc. and Ora, Inc. announce new partnership to accelerate the development of regenerative peptide therapy, BRM421 for Dry Eye Syndrome

BRIM Biotechnology, Inc. and Ora, Inc. announce new partnership to accelerate the development of regenerative peptide therapy, BRM421 for Dry Eye Syndrome

Artificial tears with demulcents can retain surface moisture and immune modulators can help to control inflammation, allowing the body’s natural healing processes to repair damage. ...

ByBRIM Biotechnology, Inc.


Jubilant Therapeutics Inc. Doses First Patient in Phase I/II Trial Evaluating JBI-802, dual inhibitor of LSD1 and HDAC6, in patients with advanced solid tumors

Jubilant Therapeutics Inc. Doses First Patient in Phase I/II Trial Evaluating JBI-802, dual inhibitor of LSD1 and HDAC6, in patients with advanced solid tumors

” Syed Kazmi, Chief Executive Officer, Jubilant Therapeutics Inc. said, “JBI-802, effectively modulates two validated oncology targets with similar affinity and quick on/off exposure kinetics, leading to synergistic anti-tumour activity with a reduced risk of thrombocytopenia. ...

ByJubilant Therapeutics Inc.


NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center’s Herbert Irving Comprehensive Cancer Center

NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center’s Herbert Irving Comprehensive Cancer Center

(Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a preclinical research collaboration with Columbia University Irving Medical Center’s (CUIMC) Herbert Irving Comprehensive Cancer Center (HICCC). ...

ByNexImmune, Inc.


NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation

NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation

Combining Zephyr’s proprietary artificial intelligence (AI) and algorithmic technology with NexImmune’s Artificial Immune Modulation (AIM) nanoparticle technology, the collaboration will seek to identify and validate optimal antigens and antigen cocktails for the development of potential new therapeutics in solid and hematological cancers. ...

ByNexImmune, Inc.


NexImmune Announces Melanoma Research Collaboration with NYU Langone’s Perlmutter Cancer Center

NexImmune Announces Melanoma Research Collaboration with NYU Langone’s Perlmutter Cancer Center

(Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a research and evaluation collaboration with The Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute designated Comprehensive Cancer Center ...

ByNexImmune, Inc.


Genmab and Synaffix Enter into $415m License Agreement for ADC Technology

Genmab and Synaffix Enter into $415m License Agreement for ADC Technology

Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. ...

BySynaffix BV


Cellworks Personalized Biosimulation Study Identifies Novel MDS Biomarkers and Immune Modulation Predictive of Therapy Response

Cellworks Personalized Biosimulation Study Identifies Novel MDS Biomarkers and Immune Modulation Predictive of Therapy Response

In the ASH Abstract 3690 study, the Cellworks Biosimulation Platform and CBM identified immune modulation as a key pathway for predicting azacitidine (AZA) response in MDS. ...

ByCellworks Research India Private Limited


Inflammatix Awarded $1.7 Million Grant From National Institutes of Health (NIH)

Inflammatix Awarded $1.7 Million Grant From National Institutes of Health (NIH)

Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host immune response to infection. While over 100 clinical trials have been conducted attempting to modulate the immune response to sepsis, there have been no successful approvals of immunomodulatory therapies. ...

ByInflammatix, Inc.


Bristol Myers Squibb exercises option to develop Exscientia’s AI-designed, immune-modulating drug candidate

Bristol Myers Squibb exercises option to develop Exscientia’s AI-designed, immune-modulating drug candidate

– August 18, 2021 – Exscientia, a clinical-stage, artificial intelligence (AI)-driven pharmatech company, today announced that Bristol Myers Squibb has elected to in-license an immune-modulating drug candidate created by Exscientia. Exscientia has two active collaborations with Bristol Myers Squibb, which together focus on multiple therapeutic areas, ...

ByExscientia


20th Annual Biotech in Europe Forum for global partnering & investments

20th Annual Biotech in Europe Forum for global partnering & investments

The patent protected Apy platform is a unique mechanism to generate protective immune response against enteric infections and to shape the intestinal microbiota in medical conditions with two applications: ApyraVax with the lead indication of Clostridioides difficile infection ApyraMed with lead indications as immune modulator in cancer and ...

ByMV BioTherapeutics SA


Bio International Convention Digital June 8-12, 2020

Bio International Convention Digital June 8-12, 2020

The patent protected Apy platform is a unique mechanism to generate protective immune response against enteric infections and to shape the intestinal microbiota in medical conditions with two applications: ApyraVax with the lead indication of Clostridioides difficile infection ApyraMed with lead indications as immune modulator in cancer and ...

ByMV BioTherapeutics SA


New company name and website

New company name and website

The patent protected Apy platform is a unique mechanism to generate protective immune response against enteric infections and to shape the intestinal microbiota in medical conditions with two applications: ApyraVax with the lead indication of Clostridioides difficile infection ApyraMed with lead indications as immune modulator in cancer and ...

ByMV BioTherapeutics SA


ORYX Confirms ParvOryx Mode of Action in Tumor Explant Model

ORYX Confirms ParvOryx Mode of Action in Tumor Explant Model

When a triple therapy consisting of ParvOryx, bevacizumab and nivolumab was applied to the explants, additional effects beyond the dual combinations or the single agents were observed This confirms clinical findings from follow-up programs, where ParvOryx had been combined with immune modulators. “We are excited that these results further substantiate what ...

ByORYX GmbH & Co. KG

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT